Go read this WSJ Health Blog post on ASCO and Tasigna. It might be embargoed.
The meeting of the American Society of Clinical Oncology that spawned an embargo break before it even got underway kicks off today, officially, in Chicago. And just in time comes a fantastic post by The Wall Street Journal’s Ron Winslow about an ASCO-related situation that my Twitter followers have already called “crazy,” “surreal,” and “head-scratchingly odd.”
These are compliments, by the way, that go along with another Twitter follower’s comment that Ron is a “genius.”
I agree, and when you read the post, you will too. I can’t possibly do it justice in a short summary, so I’ll just say that it involves Novartis’ anti-chronic myelogenous leukemia drug Tasigna, a major but un-named — for reasons you can guess — medical journal, and ASCO. Ron is honest — tongue planted only somewhat firmly in cheek, I would guess — about the risk of “being drawn and quartered” for posting it.
So go read it. And check back here tomorrow morning for a post on another aspect of an, um, closely related subject. Let’s just say I’m not the bold genius that Ron Winslow is.